The antimetabolite 5‐fluorouracil (5‐FU) is the most frequently used chemotherapy in CRC treatment, targeting thymidylate synthase (TYMS) in folate‐mediated one‐carbon metabolism (FOCM) 2. Here, TYMS is linked to colorectal carcinoma.